Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell-penetrating and cell-targeting peptides in drug delivery.
Vivès E, Schmidt J, Pèlegrin A. Vivès E, et al. Among authors: pelegrin a. Biochim Biophys Acta. 2008 Dec;1786(2):126-38. doi: 10.1016/j.bbcan.2008.03.001. Epub 2008 Apr 9. Biochim Biophys Acta. 2008. PMID: 18440319 Review.
General overview of radioimmunotherapy of solid tumors.
Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. Navarro-Teulon I, et al. Among authors: pelegrin a. Immunotherapy. 2013 May;5(5):467-87. doi: 10.2217/imt.13.34. Immunotherapy. 2013. PMID: 23638743 Review.
Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane.
Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, Bascoul-Mollevi C, Arnaud FX, Pèlegrin A, Navarro-Teulon I, Pouget JP. Paillas S, et al. Among authors: pelegrin a. Nucl Med Biol. 2013 May;40(4):471-80. doi: 10.1016/j.nucmedbio.2013.02.001. Epub 2013 Mar 19. Nucl Med Biol. 2013. PMID: 23522976 Free article.
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Bourillon L, Bourgier C, Gaborit N, Garambois V, Llès E, Zampieri A, Ogier C, Jarlier M, Radosevic-Robin N, Orsetti B, Delpech H, Theillet C, Colombo PE, Azria D, Pèlegrin A, Larbouret C, Chardès T. Bourillon L, et al. Among authors: pelegrin a. Int J Cancer. 2019 Oct 1;145(7):1838-1851. doi: 10.1002/ijc.32273. Epub 2019 Apr 1. Int J Cancer. 2019. PMID: 30882895 Free article.
Examination of HER3 targeting in cancer using monoclonal antibodies.
Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y. Gaborit N, et al. Among authors: pelegrin a. Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6. Proc Natl Acad Sci U S A. 2015. PMID: 25564668 Free PMC article.
[Bispecific antibodies: what future?].
Pèlegrin A, Robert B. Pèlegrin A, et al. Med Sci (Paris). 2009 Dec;25(12):1155-8. doi: 10.1051/medsci/200925121155. Med Sci (Paris). 2009. PMID: 20035697 Free article. Review. French.
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A. Larbouret C, et al. Among authors: pelegrin a. Neoplasia. 2012 Feb;14(2):121-30. doi: 10.1593/neo.111602. Neoplasia. 2012. PMID: 22431920 Free PMC article.
166 results